Physician profile
David R Schlessel
NPI 1962478826
$1,998.34
in general payments reported to CMS, 2019-2025
27 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $197 · 2021: $11.06 · 2022: $48.16 · 2023: $204 · 2024: $547 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $362.67 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.21 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $201.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $197.75 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.60 | 2019-2024 | Jardiance |
| Abbott Laboratories | $120.61 | 2024 | Mitraclip |
| Boston Scientific Corporation | $119.56 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $84.09 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $62.65 | 2019 | |
| Scpharmaceuticals INC. | $52.36 | 2023-2024 | |
| Edwards Lifesciences Corporation | $49.42 | 2019 | |
| Abiomed | $49.41 | 2024-2025 | Impella |
| Irhythm Technologies, INC. | $35.38 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.72 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $32.29 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $30.38 | 2024-2025 | Farxiga |
| Amarin Pharma, INC. | $26.85 | 2020 | |
| Cvrx, INC. | $23.27 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2025 | |
| Esperion Therapeutics, INC. | $16.75 | 2024 | Nexletol |
| Teleflex LLC | $14.92 | 2025 | Trapliner |
| W. L. Gore & Associates, INC. | $14.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2025 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $14.33 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.79 | 2019 | |
| Merck Sharp & Dohme LLC | $13.13 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schlessel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.